EPZ5676: Potent and Selective DOT1L Inhibitor for MLL-Rearranged Leukemia

Executive Summary: EPZ5676 (SKU A4166), developed by APExBIO, is a highly potent DOT1L histone methyltransferase inhibitor with an IC₅₀ of 0.8 nM and a Ki of 80 pM, demonstrating over 37,000-fold selectivity relative to other methyltransferases (APExBIO, product page). It competitively occupies the S-adenosyl methionine (SAM) binding pocket of DOT1L, leading to robust inhibition of H3K79 methylation (Daigle et al. 2013, DOI). EPZ5676 induces potent cytotoxicity in acute leukemia cell lines with MLL translocations, with in vivo models showing complete tumor regression without significant toxicity (Daigle et al. 2013). The compound is widely used in biochemical enzyme assays and translational leukemia research (APExBIO, product page).

Biological Rationale

DOT1L (disruptor of telomeric silencing 1-like) is a histone methyltransferase responsible for methylating lysine 79 on histone H3 (H3K79). This epigenetic modification regulates gene expression programs involved in cell proliferation, differentiation, and leukemogenesis (Anbazhagan et al., 2024). Dysregulation of DOT1L activity, especially via MLL (mixed lineage leukemia) gene rearrangements, is a hallmark of certain aggressive leukemias. Aberrant H3K79 methylation upregulates oncogenic transcriptional targets, driving leukemia cell survival and proliferation. Pharmacologic inhibition of DOT1L is therefore a rational therapeutic strategy for MLL-rearranged leukemias. By targeting this epigenetic pathway, selective inhibitors like EPZ5676 address the underlying molecular etiology rather than downstream phenotypes [see also: EPZ-5676: Potent and Selective DOT1L Inhibitor for Epigen...]—this article provides updated specificity and workflow integration data not found in the linked resource.

Mechanism of Action of DOT1L Inhibitor EPZ-5676

EPZ5676 is a SAM-competitive inhibitor that selectively binds the SAM binding pocket of DOT1L. Binding induces a conformational shift, opening a hydrophobic pocket beyond the amino acid portion of SAM, which is not present in closely related methyltransferases (Daigle et al., 2013). This selectivity is quantified by over 37,000-fold reduced activity against methyltransferases such as CARM1, EHMT1/2, EZH1/2, PRMTs, SETD7, SMYD2/3, and WHSC1/1L1. The enzyme inhibition is both potent and specific: IC₅₀ = 0.8 nM (in vitro enzyme assay), Ki = 80 pM (radiolabeled competitive binding). In cellular models, EPZ5676 blocks H3K79 methylation and downregulates MLL-fusion oncogene targets, leading to G1 arrest and apoptosis in MLL-rearranged leukemia cells. Notably, it displays minimal off-target activity in non-MLL leukemia lines and in normal hematopoietic progenitors, enhancing its translational safety window [see: EPZ5676: Next-Generation DOT1L Inhibitor for Epigenetic D...]—this article extends on mechanistic insights and in vivo selectivity data.

Evidence & Benchmarks

• EPZ5676 inhibits DOT1L enzyme activity with an IC₅₀ of 0.8 nM (in vitro, 25°C, pH 7.5, 30 min) (Daigle et al., 2013).
• Displays a Ki of 80 pM for DOT1L, indicating high-affinity binding (radioligand competition, 25°C) (Daigle et al., 2013).
• Over 37,000-fold selectivity relative to other methyltransferases in panel screens (selectivity assay, IC₅₀ > 30 µM for non-DOT1L targets) (Daigle et al., 2013).
• Antiproliferative activity in MV4-11 (MLL-AF4+) cells at IC₅₀ = 3.5 nM (cellular proliferation, 4–7 days, 37°C) (APExBIO).
• Complete tumor regression in MV4-11 xenograft models at 35–70 mg/kg/day IV for 21 days, with no significant toxicity (nude rat, 21°C, monitored for weight loss & clinical signs) (Daigle et al., 2013).
• Demonstrates robust inhibition of H3K79 methylation and MLL-fusion target gene expression (qPCR and ChIP, 24–72 hr, 37°C) ([see: EPZ-5676: Potent DOT1L Inhibitor for MLL-Rearranged Leuke...]—this article clarifies in vivo efficacy and dosing parameters).

Applications, Limits & Misconceptions

Key Applications:

• MLL-rearranged leukemia research: EPZ5676 is the leading tool compound for dissecting epigenetic dependencies in MLL-translocated leukemias.
• Histone methyltransferase inhibition assays: Used as a benchmark for enzyme selectivity and potency in biochemical and cellular platforms.
• Epigenetic regulation in cancer: Enables mechanistic studies on H3K79 methylation and gene expression in oncogenesis.
• Translational drug development: Serves as a preclinical candidate and comparator for novel DOT1L inhibitors in drug discovery pipelines.

Common Pitfalls or Misconceptions

• EPZ5676 is not effective against non-MLL-rearranged cancers; efficacy is highly context-specific.
• The compound is insoluble in water; use DMSO or ethanol (with sonication) for stock solutions (≥28.15 mg/mL in DMSO, ≥50.3 mg/mL in ethanol).
• Long-term storage of EPZ5676 solutions at ambient temperature leads to loss of potency; store at -20°C and avoid repeated freeze-thaw cycles.
• Not intended for direct clinical use; for research applications only.
• Does not inhibit class IIa HDACs or affect PTGER4 signaling as shown in unrelated rectal epithelial cell studies (Anbazhagan et al., 2024).

Workflow Integration & Parameters

EPZ5676 (APExBIO, SKU A4166) is supplied as a solid with a molecular weight of 562.71. For biochemical assays, prepare stock solutions in DMSO (≥28.15 mg/mL) or ethanol (≥50.3 mg/mL with ultrasonic assistance). The compound is insoluble in water. Store powder and DMSO stocks at -20°C; avoid light and moisture. For cellular proliferation assays, treat MV4-11 cells at 3.5 nM for 4–7 days at 37°C. For in vivo studies (e.g., MV4-11 xenografts), administer 35–70 mg/kg/day intravenously for up to 21 days, monitoring for toxicity and tumor regression (Daigle et al., 2013). For robust, reproducible results, avoid extended solution storage and calibrate dosing to model system requirements. For troubleshooting and advanced assay design, see Scenario-Driven Solutions for Reliable Assays with DOT1L ...—the present article expands on solution stability and selectivity constraints.

Conclusion & Outlook

EPZ5676 anchors the field of DOT1L inhibitor research due to its high potency, specificity, and translational relevance for MLL-rearranged leukemia. Its robust biochemical and in vivo benchmarks facilitate reliable, interpretable results in both basic research and preclinical drug development. Future studies may extend its utility to other epigenetically driven cancers or combinatorial therapeutic regimens. APExBIO continues to provide validated, stable supply of EPZ5676 (product page) for global epigenetics and leukemia research communities.